
Mission Therapeutics raises $13.3 million for Parkinson’s treatment
Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease. The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential… Read More















